Please login to the form below

Not currently logged in
Email:
Password:

Ignyta

This page shows the latest Ignyta news and features for those working in and with pharma, biotech and healthcare.

Roche’s rival to Bayer’s Vitrakvi gets speedy FDA review

Roche’s rival to Bayer’s Vitrakvi gets speedy FDA review

Roche acquired rights to entrectinib when it bought Ignyta for $1.7bn just over a year ago, having licensed rights to the drug in a $1.55bn deal a few weeks

Latest news

More from news
Approximately 1 fully matching, plus 4 partially matching documents found.

Latest Intelligence

  • Pharma deals in March 2015 Pharma deals in March 2015

    Two days' later Teva acquired four oncology development programmes (the most advanced in phase I/II) from Ignyta for $42m.

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

Latest appointments

More from appointments
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Frontera Group

Welcome to Frontera Group, where our agencies immerse you in the world of the patient...

Latest intelligence

Language barriers: Obesity has become a loaded word
...
Spotlight interview: 15 minutes on digital in medical communications
Gemma Allen, Head of Digital Communications, OPEN Health takes 15 minutes to answer some key questions on digital in medical communications...
Generating data on long-term outcomes with gene and other advanced therapies
Gene therapy and advanced cell-based therapies offer patients hope and the potential to make them ‘chronically well’....

Infographics